Celldex Therapeutics (CLDX) News Today $22.46 +0.44 (+2.00%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$22.78 +0.32 (+1.42%) As of 08/22/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CLDX Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Wellington Management Group LLP Has $151.63 Million Stock Position in Celldex Therapeutics, Inc. $CLDXAugust 23 at 5:40 AM | marketbeat.comCelldex Therapeutics, Inc. $CLDX Position Boosted by Algert Global LLCAugust 23 at 5:05 AM | marketbeat.comCelldex Therapeutics (NASDAQ:CLDX) Shares Gap Down After Analyst DowngradeAugust 22 at 10:43 AM | marketbeat.comCanaccord Genuity Group Issues Pessimistic Forecast for Celldex Therapeutics (NASDAQ:CLDX) Stock PriceAugust 22 at 10:24 AM | marketbeat.comCelldex Therapeutics (NASDAQ:CLDX) Given New $42.00 Price Target at HC WainwrightAugust 22 at 8:05 AM | marketbeat.comDeutsche Bank AG Raises Stock Holdings in Celldex Therapeutics, Inc. $CLDXAugust 22 at 3:28 AM | marketbeat.comCelldex Therapeutics (NASDAQ:CLDX) Price Target Cut to $42.00 by Analysts at HC WainwrightAugust 22 at 2:47 AM | americanbankingnews.comCitigroup Has Lowered Expectations for Celldex Therapeutics (NASDAQ:CLDX) Stock PriceAugust 22 at 2:47 AM | americanbankingnews.comCelldex slides after Barzolvolimab hits target but fails to improve EoE symptoms in phase 2 trialAugust 20 at 8:01 PM | msn.comCelldex Therapeutics (NASDAQ:CLDX) Stock Price Down 4.7% - Here's WhyAugust 20 at 4:21 PM | marketbeat.comCelldex Therapeutics Pulls Plug On Eosinophilic Esophagitis Investigational Drug As Data Falls ShortAugust 20 at 10:51 AM | benzinga.comLifeSci Capital Maintains a Buy on Celldex Therapeutics (CLDX), Keeps the PTAugust 20 at 3:49 AM | msn.comCelldex Halts Barzolvolimab Development for EoEAugust 19, 2025 | msn.comCelldex Therapeutics Inc (CLDX) Announces Phase 2 Study Results for Barzolvolimab in ...August 19, 2025 | gurufocus.comCelldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE)August 19, 2025 | globenewswire.comWellington Management Group LLP Reduces Stake in Celldex Therapeutics IncAugust 17, 2025 | gurufocus.comCelldex Therapeutics Reports Increased R&D Expenses Amid Wider LossesAugust 15, 2025 | msn.comCelldex Therapeutics (NASDAQ:CLDX) Trading Up 7.2% - Should You Buy?August 13, 2025 | marketbeat.comCelldex’s Phase 3 Study on Barzolvolimab: A Potential Game-Changer for Chronic Spontaneous UrticariaAugust 12, 2025 | tipranks.comCelldex Therapeutics, Inc. (NASDAQ:CLDX) Given Average Recommendation of "Moderate Buy" by BrokeragesAugust 11, 2025 | marketbeat.comDecoding Celldex Therapeutics Inc (CLDX): A Strategic SWOT InsightAugust 7, 2025 | gurufocus.comCelldex Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 7, 2025 | globenewswire.comCelldex Therapeutics (CLDX) Projected to Post Quarterly Earnings on ThursdayAugust 7, 2025 | marketbeat.comUniversal Beteiligungs und Servicegesellschaft mbH Buys Shares of 14,834 Celldex Therapeutics, Inc. (NASDAQ:CLDX)August 5, 2025 | marketbeat.comTD Asset Management Inc Sells 65,000 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)August 4, 2025 | marketbeat.comCelldex Therapeutics’ Phase 3 Study on Barzolvolimab: A Potential Game-Changer for Chronic UrticariaAugust 1, 2025 | tipranks.comGSA Capital Partners LLP Makes New Investment in Celldex Therapeutics, Inc. (NASDAQ:CLDX)July 31, 2025 | marketbeat.comCelldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Consensus Rating of "Moderate Buy" from BrokeragesJuly 16, 2025 | marketbeat.comCelldex Therapeutics (NASDAQ:CLDX) Share Price Passes Above 200-Day Moving Average - Should You Sell?July 4, 2025 | marketbeat.comCLDX Celldex Therapeutics, Inc. - Seeking AlphaJune 24, 2025 | seekingalpha.comCelldex Therapeutics, Inc. (NASDAQ:CLDX) Given Consensus Recommendation of "Moderate Buy" by BrokeragesJune 21, 2025 | marketbeat.comCelldex Therapeutics (NASDAQ:CLDX) Shares Down 5.5% - Should You Sell?June 16, 2025 | marketbeat.comCelldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025June 16, 2025 | morningstar.comMQ2 Earnings Estimate for CLDX Issued By Lifesci CapitalJune 16, 2025 | marketbeat.comCelldex Therapeutics’ SWOT analysis: barzolvolimab stock shows promise amid challengesJune 15, 2025 | investing.comCelldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025June 14, 2025 | globenewswire.comCelldex shares jump on impressive skin disorder drug dataJune 13, 2025 | in.investing.comCelldex Therapeutics (NASDAQ:CLDX) Trading Up 9% - Here's WhyJune 13, 2025 | marketbeat.comForecasting The Future: 8 Analyst Projections For Celldex TherapeuticsJune 13, 2025 | benzinga.comCelldex Therapeutics' (CLDX) Buy Rating Reaffirmed at HC WainwrightJune 13, 2025 | marketbeat.comCelldex Therapeutics Inc (CLDX) Reports Promising Phase 2 Results for Barzolvolimab in Chronic ...June 12, 2025 | gurufocus.comCelldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025June 12, 2025 | globenewswire.comCelldex Announces Upcoming Presentations of Barzolvolimab Phase 2 Data in Chronic Spontaneous Urticaria at EAACI 2025 CongressJune 10, 2025 | globenewswire.comEquities Analysts Issue Forecasts for CLDX FY2026 EarningsJune 10, 2025 | marketbeat.comCelldex Therapeutics (NASDAQ:CLDX) Trading Down 4.5% - Should You Sell?June 9, 2025 | marketbeat.comTwo Sigma Investments LP Buys Shares of 33,025 Celldex Therapeutics, Inc. (NASDAQ:CLDX)June 7, 2025 | marketbeat.comCelldex Therapeutics, Inc. (NASDAQ:CLDX) Shares Sold by Bank of America Corp DEJune 7, 2025 | marketbeat.comCelldex Approves Equity Plan Amendment and Elects New DirectorJune 6, 2025 | tipranks.comCelldex Therapeutics Announces Election of Denice Torres to its Board of DirectorsJune 6, 2025 | globenewswire.comApella Capital LLC Invests $309,000 in Celldex Therapeutics, Inc. (NASDAQ:CLDX)June 6, 2025 | marketbeat.com Get Celldex Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CLDX and its competitors with MarketBeat's FREE daily newsletter. Email Address CLDX Media Mentions By Week CLDX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CLDX News Sentiment▼0.050.68▲Average Medical News Sentiment CLDX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CLDX Articles This Week▼205▲CLDX Articles Average Week Get Celldex Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CLDX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Alkermes News Ligand Pharmaceuticals News Amicus Therapeutics News BioCryst Pharmaceuticals News Novavax News Innoviva News Dynavax Technologies News MannKind News OPKO Health News Geron News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CLDX) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celldex Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Celldex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access